Does the media favor MRK or SMMT?

In the previous week, Merck & Co., Inc. had 55 more articles in the media than Summit Therapeutics. MarketBeat recorded 58 mentions for Merck & Co., Inc. and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Merck & Co., Inc.'s score of 1.02 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 37 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, LPA or SMMT?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Logistic Properties of the Americas $50.13M 2.15 $10.50M N/A N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is SMMT or RVMD more profitable?

Revolution Medicines' return on equity of -83.22% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Revolution Medicines N/A -83.22% -59.06%

Does the media prefer SMMT or RVMD?

In the previous week, Revolution Medicines had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 11 mentions for Revolution Medicines and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Revolution Medicines' score of 0.63 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or SMMT?

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than Summit Therapeutics. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Teva Pharmaceutical Industries' score of 1.13 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 15 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SMMT or ONC?

In the previous week, BeOne Medicines had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 8 mentions for BeOne Medicines and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat BeOne Medicines' score of 0.77 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Summit Therapeutics (SMMT) Competitors

$15.30 +0.05 (+0.33%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$15.22 -0.08 (-0.49%)

As of 07/13/2026 07:46 PM Eastern

Compare

SMMT vs. MRK, LPA, RVMD, TEVA, and ONC

Should you buy Summit Therapeutics stock or one of its competitors? MarketBeat compares Summit Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Summit Therapeutics include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC).

How does Summit Therapeutics compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	4.71	$18.25B	$3.55	34.91
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Merck & Co., Inc. presently has a consensus price target of $133.94, suggesting a potential upside of 8.08%. Summit Therapeutics has a consensus price target of $26.97, suggesting a potential upside of 76.29%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.70
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

In the previous week, Merck & Co., Inc. had 55 more articles in the media than Summit Therapeutics. MarketBeat recorded 58 mentions for Merck & Co., Inc. and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Merck & Co., Inc.'s score of 1.02 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	37 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Merck & Co., Inc. has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

Merck & Co., Inc. has a net margin of 13.59% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 27.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
Summit Therapeutics	N/A	-291.24%	-243.07%

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Logistic Properties of the Americas (NYSEAMERICAN:LPA) and Summit Therapeutics (NASDAQ:SMMT) are related companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Logistic Properties of the Americas has a beta of 5.31, suggesting that its stock price is 431% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

Logistic Properties of the Americas has a net margin of 6.31% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 1.08% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Logistic Properties of the Americas	6.31%	1.08%	0.49%
Summit Therapeutics	N/A	-291.24%	-243.07%

Logistic Properties of the Americas currently has a consensus price target of $7.50, indicating a potential upside of 119.94%. Summit Therapeutics has a consensus price target of $26.97, indicating a potential upside of 76.29%. Given Logistic Properties of the Americas' higher probable upside, research analysts plainly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Logistic Properties of the Americas	$50.13M	2.15	$10.50M	N/A	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

42.7% of Logistic Properties of the Americas shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 32.0% of Logistic Properties of the Americas shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Summit Therapeutics had 3 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 3 mentions for Summit Therapeutics and 0 mentions for Logistic Properties of the Americas. Summit Therapeutics' average media sentiment score of 1.67 beat Logistic Properties of the Americas' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Logistic Properties of the Americas	Neutral
Summit Therapeutics	Very Positive

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Revolution Medicines?

Summit Therapeutics (NASDAQ:SMMT) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summit Therapeutics presently has a consensus target price of $26.97, suggesting a potential upside of 76.29%. Revolution Medicines has a consensus target price of $144.00, suggesting a potential downside of 21.72%. Given Summit Therapeutics' higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summit Therapeutics has higher earnings, but lower revenue than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Revolution Medicines	$11.58M	3,377.18	-$1.13B	-$7.07	N/A

In the previous week, Revolution Medicines had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 11 mentions for Revolution Medicines and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Revolution Medicines' score of 0.63 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines' return on equity of -83.22% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Revolution Medicines	N/A	-83.22%	-59.06%

Summit Therapeutics has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Summary

Revolution Medicines beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 29.94%. Summit Therapeutics has a consensus price target of $26.97, indicating a potential upside of 76.29%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than Summit Therapeutics. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat Teva Pharmaceutical Industries' score of 1.13 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	15 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Summit Therapeutics' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Summit Therapeutics	N/A	-291.24%	-243.07%

Teva Pharmaceutical Industries has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.14	$1.41B	$1.33	24.17
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Summary

Teva Pharmaceutical Industries beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to BeOne Medicines?

Summit Therapeutics (NASDAQ:SMMT) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BeOne Medicines had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 8 mentions for BeOne Medicines and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.67 beat BeOne Medicines' score of 0.77 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics presently has a consensus target price of $26.97, suggesting a potential upside of 76.29%. BeOne Medicines has a consensus target price of $391.38, suggesting a potential upside of 28.76%. Given Summit Therapeutics' higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
BeOne Medicines	$5.34B	6.24	$286.93M	$4.47	68.00

Summit Therapeutics has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Summit Therapeutics' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Summit Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.84B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-9.56	19.17	27.11	24.26
Price / Sales	N/A	838.79	587.92	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	18.00	4.22	10.75	6.29
Net Income	-$1.08B	$64.26M	$3.58B	$330.66M
7 Day Performance	-3.65%	-3.58%	-2.06%	-1.32%
1 Month Performance	9.21%	2.12%	3.32%	-0.64%
1 Year Performance	-39.76%	20.35%	26.35%	19.08%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	3.6734 of 5 stars	$15.30 +0.3%	$26.97 +76.3%	-38.8%	$11.84B	N/A	N/A	110	Positive News
MRK Merck & Co., Inc.	4.435 of 5 stars	$129.34 -0.2%	$131.83 +1.9%	+48.7%	$319.99B	$65.01B	36.43	75,000	Trending News Analyst Upgrade
LPA Logistic Properties of the Americas	3.61 of 5 stars	$3.64 flat	$7.50 +106.0%	-51.5%	$115.09M	$50.13M	36.40	30	Positive News Gap Up
RVMD Revolution Medicines	1.9594 of 5 stars	$189.24 flat	$135.39 -28.5%	+383.8%	$40.23B	$11.58M	N/A	250	Gap Down
TEVA Teva Pharmaceutical Industries	4.8057 of 5 stars	$34.55 -0.2%	$41.78 +20.9%	+96.2%	$39.83B	$17.26B	25.98	33,950	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, TEVA, and ONC

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Summit Therapeutics compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, RVMD, TEVA, and ONC

How does Summit Therapeutics compare to Merck & Co., Inc.?

Which has preferable earnings and valuation, MRK or SMMT?

Do analysts prefer MRK or SMMT?

Does the media favor MRK or SMMT?

Which has more risk and volatility, MRK or SMMT?

Is MRK or SMMT more profitable?

Do insiders and institutionals hold more shares of MRK or SMMT?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Which has more risk & volatility, LPA or SMMT?

Is LPA or SMMT more profitable?

Do analysts prefer LPA or SMMT?

Which has better valuation & earnings, LPA or SMMT?

Do institutionals and insiders have more ownership in LPA or SMMT?

Does the media favor LPA or SMMT?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Do institutionals & insiders hold more shares of SMMT or RVMD?

Do analysts rate SMMT or RVMD?

Which has better earnings & valuation, SMMT or RVMD?

Does the media prefer SMMT or RVMD?

Is SMMT or RVMD more profitable?

Which has more risk and volatility, SMMT or RVMD?

Summary

How does Summit Therapeutics compare to Teva Pharmaceutical Industries?

Do analysts prefer TEVA or SMMT?

Which has more risk & volatility, TEVA or SMMT?

Does the media favor TEVA or SMMT?

Do institutionals & insiders have more ownership in TEVA or SMMT?

Is TEVA or SMMT more profitable?

Which has better valuation and earnings, TEVA or SMMT?

Summary

How does Summit Therapeutics compare to BeOne Medicines?

Do institutionals and insiders believe in SMMT or ONC?

Does the media refer more to SMMT or ONC?

Do analysts rate SMMT or ONC?

Which has preferable earnings and valuation, SMMT or ONC?

Which has more volatility and risk, SMMT or ONC?

Is SMMT or ONC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools